Cartela R & D AB
Records under this name other than patents Cartela R & D AB holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 8 of 8 · Back to Cartela R & D AB
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,012,696 | Monoclonal Antibody Capable of Binding Integrin Alpha 10 Beta 1 Formerly held Term ended Term ended Jan 24, 2025 · High confidence | Term ended | Term ended Jan 24, 2025 | High confidence |
| US 8,563,255 | Monoclonal Antibody Capable of Binding Integrin Alpha 10 Beta 1 Formerly held Term ended Term ended Oct 31, 2024 · High confidence | Term ended | Term ended Oct 31, 2024 | High confidence |
| US 7,452,677 | Monoclonal Antibody Capable of Binding Integrin Alpha 10 Beta 1 Formerly held Term ended Term ended Apr 14, 2024 · High confidence | Term ended | Term ended Apr 14, 2024 | High confidence |
| US 7,749,710 | Marker for stem cells and its use Formerly held Term ended Term ended Aug 6, 2023 · USPTO record | Term ended | Term ended Aug 6, 2023 | USPTO record |
| US 8,105,791 | Marker for stem cells and its use Formerly held Term ended Term ended Jun 12, 2023 · USPTO record | Term ended | Term ended Jun 12, 2023 | USPTO record |
| US 7,485,429 | Integrin heterodimer and an alpha subunit thereof Formerly held Term ended Term ended Jun 27, 2020 · USPTO record | Term ended | Term ended Jun 27, 2020 | USPTO record |
| US 7,029,858 | Integrin heterodimer and a subunit thereof Formerly held Term ended Term ended Mar 31, 2019 · USPTO record | Term ended | Term ended Mar 31, 2019 | USPTO record |
| US 8,048,991 | Antibody to an integrin heterodimer and/or a subunit thereof Formerly held Term ended Ended no later than Mar 31, 2019 · USPTO record | Term ended | Ended no later than Mar 31, 2019 | USPTO record |